Back to the directory

Catena Biosciences

Using protein coupling to build new therapies

Founded
2020
Status
Active
Stage
Early
Team size
7
Location
San Francisco, CA, USA; Berkeley
Category
Biotech & Drug Discovery
Sector
Therapeutics

About Catena Biosciences

Catena’s technology lets us attach any two proteins together using an enzyme and the native amino acids tyrosine and cysteine within target proteins. It is a true platform technology because it enables the joining of any two soluble proteins together with minimal engineering and without restrictions due to protein size or complexity. Our work has already been used to modify cancer specific antibodies, CRISPR proteins and even cell surfaces. Our ability to produce modular protein therapeutics in a fraction of the time allows for true library creation across the therapeutics spectrum from oncology, vaccines, inflammatory disease and beyond.

BiotechTherapeutics

Federal research funding

1 NIH award totalling $299,379, FY2021.

  • Protein Conjugation For Antigen-Specific Treatment Of Thyroid Autoimmune Diseases

Source: NIH RePORTER.

Company data compiled and maintained by Healthcare Discovery.